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In vitro dexamethasone 
treatment does not induce 
alternative ATM transcripts 
in cells from Ataxia–Telangiectasia 
patients
Elisa Pozzi1, Elisa Giorgio1, Cecilia Mancini1, Nicola Lo Buono 2, Stefania Augeri1, 
Marta Ferrero1, Eleonora Di Gregorio3, Evelise Riberi4, Maria Vinciguerra5, Lorenzo Nanetti6, 
Federico Tommaso Bianchi7, Maria Paola Sassi 8, Vincenzo Costanzo5, Caterina Mariotti6, 
Ada Funaro 1, Simona Cavalieri1,9 & Alfredo Brusco 1,3,9*
Short term treatment with low doses of glucocorticoid analogues has been shown to ameliorate 
neurological symptoms in Ataxia–Telangiectasia (A–T), a rare autosomal recessive multisystem 
disease that mainly affects the cerebellum, immune system, and lungs. Molecular mechanisms 
underlying this clinical observation are unclear. We aimed at evaluating the effect of dexamethasone 
on the induction of alternative ATM transcripts (ATMdexa1). We showed that dexamethasone cannot 
induce an alternative ATM transcript in control and A–T lymphoblasts and primary fibroblasts, or in an 
ATM-knockout HeLa cell line. We also demonstrated that some of the reported readouts associated 
with ATMdexa1 are due to cellular artifacts and the direct induction of γH2AX by dexamethasone via 
DNA-PK. Finally, we suggest caution in interpreting dexamethasone effects in vitro for the results to 
be translated into a rational use of the drug in A–T patients.
Ataxia–Telangiectasia (A–T; MIM#208900) is a rare autosomal recessive multisystem disorder caused by bial-
lelic pathogenic variants in the ATM gene (MIM#607585). Most of these variants are null changes leading to a 
complete loss of ATM protein function. A–T patients show early-onset progressive cerebellar neurodegenera-
tion, oculocutaneous telangiectasias, immunodeficiency and a high incidence of infections and  cancers1–3. In 
classic A–T, patients are wheelchair-dependent by the age of 10 years and their life expectancy is approximately 
25  years4–6.
ATM encodes a large 3056 amino acid protein whose main role is coordinating the cellular response to DNA 
double strand  breaks7, but it is also involved in the response to oxidative stress, and other forms of genotoxic 
stress. ATM is active in cell signaling pathways involved in maintaining cellular homeostasis, and is known to 
directly phosphorylate and regulate a list of several hundreds of  substrates7–12.
Since ATM is ubiquitously expressed, the reason why cerebellar Purkinje cells are so incredibly sensitive to 
its loss, while other neurons are unaffected, is still unknown.
No effective disease-modifying therapy is presently available for A–T; however, in recent years, some studies 
have demonstrated that short-term treatments with low doses of glucocorticoids ameliorate the neurological 
symptoms of A–T patients without relevant side  effects13–17. After an observational study which suggested that 
betamethasone may improve neurologic functions in patients with A–T13, short-term trials confirmed the efficacy 
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of oral  betamethasone14. In particular, speech disturbance and stance, as well as the quality of motor coordination, 
were the most sensitive neurological  parameters14, 15, 18. A recent study suggested that a daily dose of 0.005 mg/
kg betamethasone, is effective in some A–T patients, and can be considered for occasional usage under medical 
supervision. However, the long-term side-effects versus efficacy of this treatment has not yet been  evaluated17.
Other research groups showed that infusions of autologous erythrocytes loaded with dexamethasone were 
effective in improving neurological symptoms in some A–T  patients19. This procedure takes advantage of an 
autologous erythrocyte-based drug delivery system, and is currently used in an international, multi-centre, rand-
omized, prospective, double-blind, placebo-controlled, phase III study (https ://clini caltr ials.gov/ct2/show/NCT02 
77080 7). The procedure is invasive, requiring monthly blood samples of 50 ml and subsequent  transfusions19.
The cellular/molecular mechanism(s) underlying the glucocorticoid clinical effects in A–T are currently 
unclear. Response to treatment occurs within hours, and incoordination rapidly reoccurs upon suspension of the 
drug. A–T patients, who exhibited a good motor response to betamethasone treatment had increased activation 
in relevant cortical areas has been reported, suggesting that glucocorticoids may facilitate cortical compensatory 
mechanisms on cerebellar  dysfunction20.
An explanation for the corticosteroid response in A–T patients was the description of dexamethasone induc-
tion of non-canonical ATM splicing events in A–T cell lines. Dexamethasone can allow the synthesis of a non-
canonical ATM transcript (ATMdexa1) and protein (mini-ATM), with some of the full-length ATM functions 
(Fig. 1A–D).
Here, we investigated this ATM splicing event using B-lymphoblastoid cell lines (LCLs) and fibroblasts from 
A–T patients with different ATM pathogenic variants and a HeLa CRISPR/ATM-knockout cell line model without 
finding any evidence of ATMdexa1 or other splicing anomalies induced by dexamethasone.
Materials and methods
Cell lines. A–T (Supplemental Table 1) and control LCLs were established from fresh lymphocytes infected 
by Epstein-Barr virus and maintained in RPMI-1640 medium (Sigma Aldrich, Italy) supplemented with 2 mMol 
Glutamine, 50 U/ml penicillin, 50 µg/ml streptomycin and 10% Fetal Bovine Serum (FBS, Gibco, Thermo Fisher 
Scientifics, Waltham, MA, USA).
A–T and control human primary fibroblasts were obtained from skin biopsies after overnight incubation 
in Dulbecco’s Modified Eagle Medium (DMEM, Sigma Aldrich, Italy) with 10% FBS with collagenase (160 µg/
ml) and then cultured in DMEM with 2 mMol Glutamine, 50 U/ml penicillin, 50 µg/ml streptomycin, 1 mMol 
Sodium Pyruvate and 10% FBS. Cells from passages 5 to 9 were used for all experiments, and cells from A–T 
patients and healthy controls at the same passage were compared.
HeLa CRISPR/ATM-knockout were generated using the CRISPR/Cas9 method and maintained in Minimum 
Essential Medium (Biowest #L0440), supplemented with 10% FBS, 2 mMol Glutamine, 1 mMol Sodium Pyruvate, 
0.1 mMol non-essential amino acids (NEAA), 50 U/ml penicillin, and 50 µg/ml streptomycin. All cells were 
maintained at 37 °C with 5%  CO2. Informed consent was obtained from participants for the use of blood and 
skin samples. The study was approved by the institutional Internal Review Board of the Department of Medical 
Sciences, University of Torino, and C. Besta Neurological Institute. Methods were carried out in accordance 
with the relevant guidelines and regulations. Dexamethasone doses and times (0.1 μM for 24 h and 72 h) used 
to analyse mRNA and protein expression were in accordance with published experimental  conditions21.
ATM transcript and expression analysis. Total RNA was extracted from 5 × 106 LCLs and from 2 × 105 
fibroblasts (from six A–T patients and four healthy controls) and from 2 × 105 HeLa CRISPR/ATM-knockout 
cells using the Direct-zol™ Kits- RNA extraction kit (Zymo Research, Irvine, California, USA) according to the 
manufacturer’s instructions. Retrotranscription of 1 µg RNA was carried out using the M-MLV Reverse Tran-
scriptase following the manufacturer’s instructions (Thermo Fisher Scientific, Waltham, Massachusetts, USA). 
Long range PCR for the ATM transcript (exons 2–56; reference ATM sequence NM_000051.3) was performed in 
a total volume of 50 µl with a final concentration of 200 nM of each primer (Supplemental Table 2), 400 μM of 
dNTPs, 1 × enzyme buffer and 2.5 units of LA polymerase (Takara Bio Inc., Otsu, Shiga 520–2193, Japan), using 
the following cycling parameters: 1 min at 94 °C, followed by 30 cycles of 10 s at 98 °C, and 11 min/kb at the 
annealing temperature, with a final extension at 72 °C for 10 min. Beta-actin was amplified as a control in a final 
volume of 25 µl with a final concentration of 500 nM of each primer, 200 µM of dNTPs, 1 × KAPA2G enzyme 
buffer and 0.5 units of KAPA2G Fast HotStart polymerase (KAPA Biosystems, Wilmington, MA, USA), under 
the following cycling parameters: 3 min at 95 °C, followed by 25 cycles of 15 s at 95 °C, and 15 s at 60 °C and 15 s 
at 72 °C followed by a final extension at 72 °C for 1 min. Amplification products were separated on a 0.6% or 
1% TBE-agarose gel for ATM and β-actin, respectively, then stained with 1X Midori Green DNA stain (Nippon 
Genetics Europe Gmbh) and visualized using a GelDOC apparatus (Biorad, Hercules, California, United States).
Absolute quantification by RT-qPCR. For an absolute quantification of full-length ATM and ATMdexa1 
transcripts, we designed three different reverse-transcription quantitative real-time PCR (RT-qPCR) assays 
using the Universal Probe Library method (UPL, Roche, Mannheim, Germany), namely (1) an ATMdexa1-
specific assay (primers on cDNA spanning the exons 3–53 junction); (2) a full-length ATM specific assay (prim-
ers on cDNA spanning the exons 14–15 junction); and (3) an ATM assay able to detect both full length and 
ATMdexa1 (primers on cDNA spanning the exons 3–4 junction) (Fig. 1E). Amplifications were carried out on 
an ABI-Prism 7500 Fast instrument, using the ABI 2X TaqMan Gene Expression master mix, according to the 
manufacturer’s instructions (Applied Biosystems, Thermo Fisher Scientific).
To obtain an absolute quantification, we generated three calibration curves, exploiting two plasmid vectors 
containing either the full-length ATM coding sequence (pMAT  plasmid22) or an artificial ATMdexa1 amplimer 
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Figure 1.  ATM and ATMdexa1 transcripts and their encoded proteins; MTT assay and cDNA analysis. (A) Full-length ATM 
transcript (NM_000051.3) with the first ATG (methionine) and termination codon (TER). The approximate position of the pathogenic 
variants in the A–T patients used in this study are indicated. (B) The ATMdexa1 variant transcript was previously reported  by21. No 
GT-AG canonical intronic consensus splicing sequences are present at the exon 4 and 53 boundaries; hence, an uncommon splicing 
event should occur between two internal sequences within these exons. Both exon 4 and exon 53 breakpoints in ATMdexa1 are 
reported to be flanked by a “cctca” sequence (in red). The first ATG within exon 58 and the termination codon in exon 63 (TER) are 
indicated. Arrows in exon 2 and exon 56 indicate forward and reverse primers used for ATM cDNA analysis (Fig. 2C). The encoded 
proteins of the two transcripts are illustrated in panels (C) (ATMdexa1- > mini-ATM) and (D) (full length ATM- > ATM). The main 
domains of the ATM protein are coloured as such: FAT (FRAP, ATM and TRRAP; a.a. 1960–2566 orange), PI3 kinase-domain 
(PI3K; a.a. 2712–2962 light blue), and FATC (FRAP, ATM and TRRAP C-terminal; a.a. 2963–3056 blue). The positions of auto-
phosphorylation sites in ATM are indicated (Ser367, Ser1893, Ser1981 and Ser2996). (E) Schematic representation of the primers 
used for RT-qPCR assays. Primers mapping on exons 3 (forward) and 4 (reverse) (yellow arrows) can detect both full-length ATM 
and ATMdexa1. Primers mapping on exon 14 (forward) and 15 (reverse) can amplify full-length ATM but not ATMdexa1 (blue 
arrows). Primers mapping on exon 3 (forward) and 53 (reverse) should amplify ATMdexa1 and are unable to amplify full-length 
ATM. (F) MTT cell viability assay performed on control cell lines after treatment with dexamethasone. LCLs were treated with 
dexamethasone for 24 h at different concentrations of the drug (0.1 μM, 1 μM and 10 μM). As a control, cells were cultured with 
0.1% EtOH. Histograms display the percentage of viable cells after treatment. The MTT assay data were analysed using the Graph 
Pad Prism 6.0 software, one-way ANOVA followed by the Bonferroni post hoc test (*p < 0.05, **p < 0.01, ***p < 0.001 vs. control cells; 
ns not significant). G. ATM transcripts visualization by long-range PCR and agarose gel in six A–T (variants are indicated in Fig. 1A 
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(pGEM-ATMdexa1 plasmid). This was generated by the overlap-extension method described in Supplemental 
Fig. 1. Each plasmid was prepared at an initial concentration of 1 × 106 copies/µL and a dilution series was pre-
pared (#copies/µL:  103, 5 × 103,  104, 5 × 104,  105, 5 × 105). Each dilution was performed in triplicate and the mean 
was used as a reference to calculate the calibration curve (Supplemental Table 3). Three A–T and control human 
LCLs treated with vehicle (EtOH) or with 0.1 µM dexamethasone were tested using the above UPL assays and 
the number of mRNA copies was inferred interpolating the Ct values to standard curves (Supplemental Table 4 
in dataset 1).
Western blotting. Total protein lysates were extracted from LCLs and primary fibroblasts of six A–T 
patients and four healthy controls, using RIPA Lysis Buffer [Tris–Cl (50 mM, pH 7.5), NaCl (150 mM), NP40 
(1%), Na Deoxycholate (0.5%), DTT (0.1 M), EDTA (5 mM), HaltTM Protease and Phosphatase inhibitor cock-
tail (Thermo Fisher Scientific)]. Nuclear lysates were extracted from fibroblasts using NE-PER Nuclear and 
Cytoplasmic Extraction Kit following the manufacturer’s protocol (Thermo Fisher Scientific). Protein quanti-
fication was measured using the Bradford assay (Bio-Rad) according to the manufacturer’s protocol. Protein 
lysates (20 µg) were denatured for 10 min at 70  °C in LaemmLi Sample Buffer (4% SDS, 20% glycerol, 10% 
2-mercaptoethanol, 0.004% bromophenol blue and 125 mM Tris HCl, pH 6.8) and reducing agent (50 mM dithi-
othreitol, DTT), resolved by SDS–PAGE (4–12%), using Tris–Glycine-SDS buffer (Thermo Fisher Scientific) and 
electro-transferred onto nitrocellulose membranes (Bio-Rad) for 1 hr at 125 V. Membranes were blocked with 
TBS-T [50 mM Tris and 150 mM NaCl, pH 7.6, and 0.1% Tween-20 (Sigma, Italy)] with 5% BSA and probed 
with primary antibodies against ATM  (2C1) (1:400; Ab sc. 23921, Santa Cruz Biotechnology, Italy), p-ATM 
(1:5000; Ab Cat. No. 32420, Abcam, Italy), γH2AX (1:3000; Ab Cat. No. NB100-384, Novus, Europe). β-Actin 
(1:2000; Cat. No. NB600-532H, Novus, Europe) or Vinculin (1:2000; Cat. No. AB6039, Merck Millipore, Italy) 
antibodies were used as loading controls. For western blot analyses, cells were incubated for 72 h in RPMI or 
DMEM medium supplemented with 5% FBS, before lysis for extraction of total or nuclear proteins. Band density 
was quantified by densitometric analysis using the Image Lab 3.0 software (Bio-Rad).
LCLs and fibroblasts were irradiated at a dose rate of 10 Gy/min at a distance of 40 cm (Radgil, Gilardoni 
Instruments, Italy). Inhibition of DNA-PK kinase activity was performed by adding 10 μM NU7441 (Sigma 
Aldrich) for 1 h to untreated cells or cells pre-treated with 0.1 μM dexamethasone for 72 h before irradiation 
(IR). Cells were then incubated at 37 °C for 1 h before nuclear protein extraction. Drugs were maintained in 
growth medium until time of harvest.
Statistical analyses. Experiments were performed in triplicate and repeated at least twice, unless other-
wise specified. Values are given as means and standard deviations, or as fold-changes. Mean values of variables 
with a normal distribution were reported, and comparisons between control groups and patient groups were 
conducted using the Student’s t test. When the distribution of data was not normal (densitometry analyses of all 
western blots), variables were presented as median values, and differences between two groups were calculated 
using the Mann–Whitney test. Significance of gene expression and enzyme activity data was calculated using the 
Student’s t test (unpaired). Statistical calculations were performed using GraphPad Statistics Software Version 
6.0 (GraphPad Software, Inc., USA). p values of < 0.05 were considered statistically significant.
Results and discussion
The proposed use of glucocorticoids for A–T therapy has prompted in vitro studies aimed at analysing their 
possible compensating role of ATM deficiency. Our initial aim was to unravel the effect of glucosteroids on A–T 
lymphoblastoid cells and primary fibroblasts, two cell types widely used as experimental models in this disease. 
Dexamethasone has been reported to induce ATM alternative splicing, resulting in the ATMdexa1 transcript, 
which encodes a functional mini-ATM  protein21, 23.
To validate this finding, we generated five A–T lymphoblastoid cell lines (LCLs) with ATM gene pathogenic 
variants outside the ATMdexa1 encoding exons on one or both alleles, and one LCL (AT-38) who carried two 
nonsense variants in exons 63 and 65 included in ATMdexa1 (Fig. 1A and Supplemental Table 1). To verify the 
effects of dexamethasone on cell viability, we performed an MTT viability assay, treating control LCLs with 
increasing doses of the drug (0.1, 1, or 10 µM for 24 h). Dexamethasone showed a modest but significant decrease 
in viability with doses ≥ 1 µM (Fig. 1F), which largely exceeds the dose of 0.1 µM for 24 h alleged to induce ATM-
dexa1 in vitro. Following the previously published  protocol21, we tested the effect of dexamethasone on ATM 
transcripts in both LCLs and fibroblasts (0.1 µM, 24 h). Using a forward primer on exon 2 and a reverse primer 
on exon 56 of the ATM cDNA (NM_00051.3), we were able to amplify the native ATM transcript (~ 9.0 kb) in 
both treated and untreated cells (Fig. 1G). No changes were observed after treatment in band intensity or in the 
appearance of additional bands corresponding to the size expected for ATMdexa1 (~ 1.6 kb). Even if we increased 
dexamethasone by tenfold compared with the suggested protocol and enhanced gel contrast (1 µM dexametha-
sone for 24 h), no additional band was detectable (Supplemental Fig. 2). Analogous results were obtained in pri-
mary fibroblast cultures from six A–T patients and four healthy controls, and in a HeLa CRISPR/ATM-knockout 
cell line (4C18) (data not shown).
To have a quantitative measure of ATM transcripts, and evaluate the detection limits of our technique, we set 
up three real-time quantification assays for ATM able to detect: 1) full-length ATM and ATMdexa1; 2) full-length 
ATM only transcripts; 3) ATMdexa1 transcripts. To generate the calibration curves, we used a serial dilution 
from  103 to  106 copies of a plasmid containing full-length ATM (pMAT) and a plasmid containing ATMdexa1, 
generated in our laboratory (pGEM-ATMdexa1 plasmid). We were able to clearly detect as low as  103 copies of 
both full ATM and ATMdexa1, although this was not the lower limit of the test (Fig. 2B). The ATM transcript was 
expressed at 63 ± 22% (median ± S.D.) in A–T cases versus controls (Fig. 2C), without any relevant differences 
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between untreated cells or cells treated with dexamethasone, apart from the CTR3 treated cell line (Fig. 2C). We 
were unable to detect ATMdexa1 in any sample (Fig. 2C). Notably, there was no difference between the number 
of cDNA copies estimated by the full-length ATM assay, which includes all ATM transcripts, and the full-length 
ATM specific assay, which does not include ATMdexa1. This further corroborates the absence of an ATMdexa1 
transcript.
Using the 2C1 antibody, raised against the C-terminal portion of the ATM protein (aa. 2577–3056), we were 
able to reveal a unique band corresponding to the native ATM in control fibroblasts but not in A-T fibroblasts. 
No additional proteins were evident, further proving the absence of mini-ATM (Fig. 2C).
Since ATMdexa1 was reported in both stimulated and non-stimulated cells, we searched available databases 
(UCSC, ENSEMBL) to have in-silico evidence of the ATMdexa1 transcript. ATM had a single validated protein-
encoding transcript (NM_000051.3), and some shorter transcripts, none of which had any similarity with the 
ATMdexa1.
A previous  study21, also raised unanswered questions on how ATMdexa1 is formed: (1) an atypical splicing 
event should take place between exons 4 and 53, without any canonical splicing site. The authors state this can 
happen by a rare SDR-splicing, reported only once in Oryza sativa, and never described in  Metazoa24; (2) the 
generation of the “mini-ATM” protein starts from a non-canonical ATG-encoding first methionine within exon 
58 (Met 2806), in the absence of a translational-initiation consensus. This ATG would produce an ATM variant 
protein beginning from codon  841821, and lacking the N-terminal, which carries nuclear localization sequences, 
several critical phosphorylation sites, and binding sites for chromatin and ATM-interacting proteins. Published 
data are against the notion that such a protein is functional, at least for its nuclear activity. ATM without the 
N-terminus is unable to fully localize to the nucleus and therefore activate DNA repair  effectors7, 25–28.
Figure 2.  Absolute reverse-transcription quantification of ATM transcripts and ATM western blot. (A) 
Calibration curves for the three RT-qPCR assays shown in Fig. 1E. Y-axis reports the Ct values obtained from 
quantitative real time analysis; on the X-axis, the number of plasmid copies used (data in Supplemental Table 3). 
For full-length ATM, we used a plasmid containing the entire gene coding region (pMAT); for ATMdexa1 we 
generated a specific plasmid as described in Supplemental Fig. 1. (B) Absolute PCR quantification, in number of 
copies, of the full-length ATM and ATMdexa1 transcripts in three A–T cell lines and three controls, treated with 
solvent (EtOH) or dexamethasone. We did not detect ATMdexa1 in any case (Supplemental Table 4 in dataset 
1). (C) Western blot analysis of the ATM protein in control (CTR1) and A-T46 fibroblasts; cells were treated 
with vehicle (EtOH), 300 μM of t-butyl hydroperoxide (TBH) or dexamethasone at increasing concentrations 
(tenfold increase from 0.1 to 100 µM). Cell lysates were analyzed by western blotting using Memcode as 
reference (left panel) or the ATM 2C1 antibody, specific for the C-terminal portion of the ATM protein (aa. 
2577–3056). No bands beyond ATM were visible on the gel. Histograms show the quantitative analysis of ATM 
in CTR1 and A-T46.
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To assess if dexamethasone influences known ATM-pathway substrates, in the absence of ATM itself, we 
measured the phosphorylation of H2AX at Ser139 (γH2AX), a sensitive marker of DNA damage  responses29. 
We analyzed the expression of γH2AX in our A–T LCLs, both at a basal level and after 72 h of treatment with 
0.1 µM dexamethasone. We found a basal phosphorylation of H2AX in both A–T and control LCLs, which 
increased by ~ 30–40% after dexamethasone treatment. Similar results were obtained after DNA double-strand 
break (DSB) induction by ionizing radiation (IR), with an additive effect of dexamethasone and IR combined 
treatment (Fig. 3A).
This result suggests that LCLs that are EBV-transformed cell lines are not a reliable cellular model to study 
dexamethasone  effects30. Our data suggest a possible role of dexamethasone in activating H2AX, regardless of 
DSB damage, and explain part of the results attributed to ATMdexa121. Histone H2AX is a substrate of several 
phosphoinositide 3-kinase-related protein kinases (PIKKs): besides ATM, ATR (ATM and Rad3-related) phos-
phorylates H2AX in response to single-stranded DNA breaks and during replication  stress31–34, and DNA-PK 
(DNA-dependent protein kinase) mediates phosphorylation of H2AX in cells under hypertonic conditions and 
during apoptotic DNA  fragmentation24, 25, 35, 36. Finally, several reports in the literature have shown that LCLs 
have such an inter-experimental variability that it can be concluded that they are an unsuitable model for DNA 
repair  studies30, 37, 38.
We therefore decided to analyze H2AX activation in response to dexamethasone in primary cells, such as 
fibroblasts, in which basal γH2AX was almost undetectable (Fig. 3B). After irradiation, H2AX was phosphoryl-
ated in control fibroblasts and, to a lesser extent, in A–T fibroblasts, as expected, due to the absence of the ATM 
Figure 3.  Analysis of the activity of ATM substrates activity. (A) Western blot analysis of H2AX Ser-139 
phosphorylation (γH2AX) on nuclear extracts from LCLs. Dexa 0.1 µM indicates dexamethasone treatment 
for 72 h; 10 Gy = 10-grey ionizing radiation (IR). Cells were harvested at 1 h after IR. Histograms on the right 
represent the densitometry analysis (mean ± SE; n = 3); fold-change was normalized on untreated control 
samples. (B) Western blot analysis shows γH2AX levels in nuclear extracts of fibroblasts after dexamethasone 
treatment and/or IR stimulation in the presence or absence of 10 µM NU7441, an inhibitor of DNA-PK kinase 
activity (1 h before IR). Inhibition of DNA-PK by NU7441(1 h before IR) reduces γH2AX, showing a role for 
DNA-PK in this pathway. Cells were harvested 1 h after IR. A representative western blot from patient A-T34 is 
shown (see also Supplemental Fig. 3). ATM phosphorylation measured using p-ATM Ab demonstrates the ATM 
activation in control cells. Histograms are representative of three independent experiments performed with two 
A–T patients’ (A-T34 and A-T46) and two control fibroblasts; fold-change was normalized on untreated control 
samples. (**p < 0.01; ns not significant).
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protein in A–T fibroblasts. We noticed dexamethasone did not increase γH2AX, either alone or in combination 
with IR (Fig. 3B).
Experimental data from other groups reported that DNA-PK can vicariate ATM in the DNA damage 
 response39–42. Hence, we assessed the role of DNA-PK in H2AX activation using NU7441, a specific DNA-PK 
inhibitor. H2AX phosphorylation was reduced in irradiated A–T fibroblasts treated with NU7441 (Fig. 3B; 
p < 0.01; ~ 30% decrease; Supplemental Fig. 2). In this experimental condition, dexamethasone treatment did 
not affect γH2AX levels. Dexamethasone can only increase γH2AX levels in LCLs, but not in A–T and control 
fibroblasts, probably because LCLs undergo significant transformations to become immortal, which can alter 
the biology of the  cell37.
In conclusion, our data and literature do not support the effect of dexamethasone on inducing ATM alterna-
tive transcripts. We reiterate that LCLs are not a suitable model to study H2AX activation, possibly due to their 
rapid replication. Taken together, our results suggest alternative explanations to ATMdexa1 must be considered 
in interpreting the in vivo effects of dexamethasone in A–T treatment.
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